Eli Lilly's Foundayo Poised to Disrupt Oral GLP-1 Market, Challenging Wegovy's Dominance

Foundayo vs. Wegovy: The Battle for the Oral GLP-1 Crown

Eli Lilly's Foundayo Secures Key FDA Approval

In a significant development this month, Eli Lilly and Company (LLY) successfully obtained U.S. Food and Drug Administration (FDA) approval for its new once-daily oral obesity medication, orforglipron, marketed under the brand name Foundayo. This approval positions Foundayo as only the second oral GLP-1 treatment available, entering a rapidly expanding and highly anticipated market.

The Rise of Oral GLP-1 Medications: A New Era for Weight Management

Foundayo's market entry follows closely on the heels of Novo Nordisk A/S's (NVO) launch of an oral version of its popular weight-loss drug, Wegovy, in January. The introduction of these oral treatments represents a major shift from traditional injectable GLP-1 agonists, offering patients a more convenient and potentially more accessible option for managing obesity.

Revenue Projections: Foundayo Aims to Challenge Wegovy's Early Lead

Initial financial forecasts indicate that Foundayo is projected to generate approximately $1.6 billion in revenue by 2026. This figure stands in contrast to Wegovy's anticipated $11.4 billion for the same year. However, as market competition intensifies, Wegovy's projected revenue is expected to slightly decrease from roughly $12.4 billion in 2025. This suggests that Foundayo is poised to capture a significant share of the market, gradually narrowing the gap with its established competitor.